Clinical Trial Update: Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial from Fudan University is evaluating treatment response adapted hybrid radiotherapy as first-line therapy for metastatic non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fudan University | Conditions: NSCLC Stage IV | Phase 2 | Status: RECRUITING